Abstract Background: Treatment options after first-line chemotherapy are limited in non-small cell lung cancer (NSCLC). Belagenpumatucel-L is a therapeutic vaccine comprised of 4 transforming growth factor (TGF)-b2-antisense gene-modified, irradiated, allogeneic NSCLC cell lines that may be useful for maintenance after initial treatment. Methods: Stage III/IV NSCLC patients who did not progress after platinum-based chemotherapy were randomised 1:1 to receive maintenance belagenpumatucel-L or placebo. Patients were eligible for randomisation between one and four months from the end of induction chemotherapy. The primary endpoint was overall survival. Results: This phase III trial enrolled 270 patients in the belagenpumatucel-L arm and 262 in the control arm. Belagenpumatucel-L was well tolerated with no serious safety concerns. There was no difference in survival between the arms (median survival 20.3 versus 17.8 months with belagenpumatucel-L versus placebo, respectively; hazard ratio (HR) 0.94, p = 0.594). There were also no differences in progression-free survival (4.3 months versus 4.0 for belagenpumatucel-L vs placebo, respectively; HR 0.99, p = 0.947). A prespecified Cox regression analysis demonstrated that the time elapsed between randomisation and the end of induction chemotherapy had a significant impact on survival (p = 0.002) and that prior radiation was a positive prognostic factor (median survival 28.4 months with belagenpumatucel-L versus 16.0 months with placebo; HR 0.61, p = 0.032). Conclusions: Although the overall trial did not meet its survival endpoint, improved survival for belagenpumatucel-L is suggested in patients who were randomised within 12 weeks of completion of chemotherapy and in those who had received prior radiation. Further studies of belagenpumatucel-L in NSCLC are warranted.
Introduction
Lung cancer is the most prevalent cancer in the western world, with approximately 224,000 new cases and 159,000 deaths expected in the United States in 2014 [1] , and 187,000 deaths in the European Union [2] .
Most patients with advanced non-small cell lung cancer (NSCLC) are initially treated with four to six cycles of platinum-based doublet chemotherapy [3] [4] [5] but five-year survival of stage IIIB/IV patients is less than 10% [6] . Patients without progression following frontline chemotherapy may be placed on maintenance therapy. Patients with non-squamous cell carcinoma who receive maintenance pemetrexed show a moderate survival benefit [7] . Maintenance with erlotinib, a molecule targeting the epidermal growth factor receptor (EGFR), is approved for all NSCLC histologies [8] , although it is most frequently used in EGFR mutant adenocarcinoma patients [3] .
Immunotherapy trials performed in NSCLC have included whole tumour cell vaccines [9] [10] [11] [12] , single tumour-associated peptides such as MUC1, telomerase, epidermal growth factor, WT1 [13] [14] [15] [16] , multiple tumour-associated peptides [17] and dendritic cells pulsed with tumour cells [18] .
Belagenpumatucel-L is an allogeneic whole tumour cell vaccine comprised of four NSCLC cell lines that were transfected with a human transforming growth factor (TGF)-b2-antisense vector designated pCHEK/HBA2 [9, 10, 19] . Two previous Phase II trials have demonstrated the safety and efficacy of belagenpumatucel-L in patients with NSCLC [9, 10] . We report on the results of a randomised, placebo-controlled Phase III study to investigate the efficacy of belagenpumatucel-L as a maintenance therapy in patients not progressing following frontline platinum-based chemotherapy.
Patients and methods

Study design
Patients with advanced NSCLC were randomised to receive maintenance belagenpumatucel-L (2.5 Â 10 7 cells per dose) or placebo in a 1:1 ratio in this international, double blind, intention to treat (ITT) study (NCT00676507).
Inclusion criteria included histologically confirmed diagnosis of stage IIIA (T3N2), IIIB or IV NSCLC [20] . Patients had stable disease or response following up to 6 cycles of a platinum-based frontline chemotherapy regimen, with or without radiation therapy. Patients had to be 18-75 years of age with an ECOG performance status of 0, 1 or 2 and an estimated life expectancy of at least 12 weeks. Other eligibility criteria were haemoglobin P 9 g/dL, albumin levels P 2.5 g/dL, bilirubin 6 1.5 times the upper limit of normal (ULN), aspartate transaminase and alanine transaminase 6 1.5 Â ULN, creatinine 6 1.5 Â ULN, alkaline phosphatase 6 5 Â ULN. Patients were eligible to be randomised between one and four months (4-17.4 weeks) following the completion of frontline chemotherapy. Patients must not have received other antitumour therapies within four weeks of randomisation.
Exclusion criteria included concurrent systemic steroids, bone metastases that required immediate therapy, uncontrolled pleural effusions, serious non-malignant disease and previous malignancies unless in remission for P2 years. 
Randomisation and stratification
An interactive voice-activated response system (IVRS) controlled patient randomisation and stratification. Patients, investigators, study team members and the sponsor were all blinded to the treatment assignment.
The Pocock and Simon minimisation method [21] was used to randomise patients into treatment and control arms while accounting for the different strata. The patients were stratified by stage (IIIA versus IIIB/IV), brain metastases, radiation during frontline chemotherapy and bevacizumab during frontline chemotherapy.
Procedures
Patients were eligible to receive up to 20 cycles of treatment; 18 cycles of monthly intradermal injections followed by two quarterly cycles of intradermal injections. Patients were removed from treatment upon disease progression or physician/patient decision to receive other treatments. Off-treatment patients were followed for survival.
Belagenpumatucel-L is comprised of four NSCLC cell lines, SK-LU1/HBA2 (adenocarcinoma), H520/HBA2 (squamous cell carcinoma), RH2/HBA2 (squamous cell carcinoma) and H460/HBA/2 (large cell carcinoma). Each cell line was transfected by electroporation with TGF-b2 antisense as previously described [9, 10] . The cells were grown in adherent cultures under cGMP conditions. The cultures were harvested, irradiated with 10,000 cGy and cryopreserved in Plasma-Lyte A (Baxter Healthcare, Marion, NC) containing 10% human serum albumin (Baxter Healthcare, Westlake Village, CA) and 10% dimethyl sulfoxide (DMSO; Bioniche Teo, Galway, Ireland). At the pharmacy the cells were thawed, mixed and 2.5 Â 10 7 total cells were injected intradermally into the upper arm. Placebo consisted of 0.15% Intralipid Ò in solution composed of the cryopreservation formulation minus the DMSO.
The determination of tumour response to frontline chemotherapy was made by an independent radiology organisation (World Care Clinical, Boston, MA) by comparing pre-randomisation CT scans to end-of-chemotherapy scans. MRIs of the brain were also compared. If present, brain metastases must have been treated and remained stable for at least 2 months prior to study enrolment.
During the trial, patients were evaluated using standard blood panels and chemistries, physical examination and limited neurologic examinations. CT scans were performed every three months. For patients enrolled with stable brain metastases, MRI scans of the brain were performed every 3 months.
Statistical analyses
The primary efficacy endpoint of this clinical trial was overall survival (OS) of patients randomised to belagenpumatucel-L compared to patients randomised to placebo. OS was calculated from the date of randomisation to the date of death from any cause. Patients who were alive or lost-to-follow-up were censored at the last known date of contact. Survival distributions were estimated using Kaplan-Meier and the primary analysis was conducted using a two-sided log rank test. The trial was powered to detect a 3.5-month survival advantage for belagenpumatucel-L assuming a 10.5-month median OS for placebo [22] . Two interim analyses were performed. The first interim analysis was performed after 140 events and the second was performed after 210 events. The overall type-1 error rate was established at 0.0016 for the first interim analysis, 0.01 for the second interim analysis and 0.046 for the final analysis. The analyses were performed by an independent data safety monitoring committee.
Secondary efficacy endpoints included progressionfree survival (PFS) and tumour response by RECIST. The Statistical Analysis Plan also prespecified additional analyses using the Cox proportional hazards regression model to assess the influence of time elapsed from the end of frontline chemotherapy to randomisation, histology, stage, prior radiation therapy, brain metastases, prior bevacizumab therapy, performance status, gender, age, clinical site, prior surgery, prior hormone therapy, prior immunotherapy and prior steroid therapy on OS. Based on two other maintenance studies [7, 23] that limited enrolment to 6 and 12 weeks following the completion of frontline chemotherapy, time elapsed was categorised as less than or equal to 12 weeks (84 days) or greater than 12 weeks.
Results
Demographics
This international, randomised, double-blind, placebo controlled study enrolled 532 patients in 73 centres in 8 countries between August 2008 and June 2012. The dataset was locked after the second interim analysis.
The belagenpumatucel-L and placebo arms were well balanced for baseline characteristics (Table 1) . 220 patients (41.4%) were randomised in North America, 284 patients (53.4%) were randomised in Europe and 28 patients (5.3%) were randomised in India.
Overall survival (OS)
The study was terminated at the second interim analysis for futility. The median ITT OS was 20.3 months (95% CI, 16.8-23.7) for belagenpumatucel-L compared to 17.8 months (95% CI, 13.7-22.0) for placebo (hazard ratio (HR) 0.94, 95% CI, 0.73-1.20; p = 0.594) (Fig. 1A) .
The OS and hazard ratios of the baseline characteristics, including the stratification criteria, are shown in Table 2 . A prespecified Cox regression analysis showed a trend towards improved survival for patients who received belagenpumatucel-L within 12 weeks of the completion of frontline chemotherapy. No correlations with survival were seen with stage, presence of brain metastases, prior treatment with bevacizumab, age, gender, histology or racial/ethnic background. In the 318 patients who were randomised within 12 weeks of the completion of frontline chemotherapy (169 in the belagenpumatucel-L arm and 149 in the placebo arm) median OS for vaccine patients was 20.7 months (95% CI 14.6-26.9) and median OS for placebo patients was 13.4 months (95% CI 9.9-16.7) (HR 0.77, 95% CI 0.56-1.05; p = 0.092) (see Fig. 1B) .
A prespecified analysis showed that patients who received chemoradiation therapy (chemoRT) prior to randomisation demonstrated better survival in the belagenpumatucel-L arm. There were 161 patients who received chemoRT prior to randomisation; 78 in the belagenpumatucel-L arm and 83 in the placebo arm. The main characteristics of these groups were well balanced. As shown in Fig. 2A (Fig. 2B) . Patients who received RT less than or equal to 6 months prior to randomisation had better survival than patients who received RT more than 6 months prior, whereas in the placebo arm there was no difference between the two groups (Table 3 ).
Secondary end-points
There was no significant difference in PFS between the treatment arms. Median PFS was 4. In the belagenpumatucel-L arm there were 6 documented partial responses and one documented complete response for a response rate of 2.5%. In the placebo arm there was one documented partial response for a response rate of 0.4% (p = 0.123; Fisher's exact test).
Safety and toxicity
There were 81 Serious Adverse Events (SAEs) reported; 49 in the belagenpumatucel-L arm and 32 in the placebo arm. Seventy-six (93.8%) of these events were not drug-related as reported by the investigator. Five events were reported by the blinded investigator to be possibly or probably drug-related. One instance of cellulitis was reported in the control arm. Three instances of leptomeningeal carcinomatosis were reported, two in the belagenpumatucel-L arm and one in the control arm. Because these events occurred in both arms it is unclear that there was a relationship between the events and administration of belagenpumatucel-L.
There was one allergic reaction related to the administration of belagenpumatucel-L, characterised by a grade 2 rash on the upper body and arms, which appeared after injection 5 and was exacerbated by injection 6 a month later. The patient was removed from treatment and the event resolved a month later.
The grade 1 and 2 Adverse Events (AEs) that were reported more than 20 times are shown in Table 4 . Table 5 shows a summary of the documented systemic anticancer therapies received after patients discontinued treatment on the study. 145 patients (54%) in the belagenpumatucel-L cohort and 138 (53%) in the control cohort received systemic anticancer therapy after withdrawal from the study. The most frequent agents used were pemetrexed, erlotinib and docetaxel.
Post-study treatments
Discussion
This large double-blind randomised study failed to demonstrate a significant increase in survival of belagenpumatucel-L as a maintenance therapy in the overall patient population with stage III/IV NSCLC who had stable disease after frontline therapy.
A prespecified Cox regression analysis suggests the importance of the time elapsed between completion of chemotherapy and randomisation (p = 0.002). Patients randomised within 12 weeks of the completion of frontline chemotherapy had 20.7-month median survival in the belagenpumatucel-L arm compared to 13.3-month median survival for the placebo arm (p = 0.092). Of the 532 patients enrolled in the trial, 214 (40%) were randomised more than 12 weeks following the completion of frontline chemotherapy, raising the possibility that one reason why this trial did not meet the primary endpoint was due to late enrolment after induction therapy.
These data do not control the inflated type I errors due to multiple testing and are therefore considered to be exploratory analyses.
Chemotherapy induces phenotypic changes in tumour cells, including upregulation of Fas, calreticulin and MHC class I, that make cells more sensitive to lysis by cytotoxic T-lymphocytes [24] [25] [26] [27] [28] . Enrolment of patients more than 12 weeks following induction may allow time for these effects to dissipate and for the tumour phenotype to revert to its less sensitive pre-chemotherapy condition [24] [25] [26] [27] .
Leucopaenia induced by platinum-based chemotherapy regimens is one of the limiting toxicities for the treatment of NSCLC [29, 30] . However, not all immune effector subsets are equally affected by chemotherapy and different subsets show different kinetics during and following chemotherapy [24, [31] [32] [33] [34] . Studies have shown a sustained depletion of the Foxp3 + CD127 lo regulatory T cell subset (Tregs) following platinum-based chemotherapy [24, 28, 33] . Chemotherapy induces decreases in the ratio of Tregs to both CD4 + T cells [24, 31, 34] and CD8 + T cells [31, 33, 34 ]. An increase in the Th1 subset of T cells has also been shown to coincide with the decrease in Tregs following platinum-based chemotherapy [31] . All of these result in a beneficial antitumour immune environment that is associated with better survival [33] . Randomising patients more than 12 weeks following the completion of chemotherapy gives the Tregs time to regenerate and allows the immune system to revert to the immunosuppressive pre-chemotherapy state. Thus, our further evaluation of the study population within 12 weeks following the completion of chemotherapy to define optimal activity of belagenpumatucel-L is in line with other maintenance therapies [7, 23] .
A prespecified analysis showed a survival advantage for patients who received chemoRT prior to receiving belagenpumatucel-L (HR 0.61, p = 0.032). Tumour radiation exerts a number of effects that are beneficial for antitumour immunity [35] . Radiation upregulates MHC class I, increases the pool of peptides presented by the class I molecules [36] and alters the phenotype of Tregs, which significantly impairs their immunosuppressive function [37] . Although tumour radiation induces a significant reduction in both T and B cells, the reduction in Tregs is greater and more long lasting than in conventional T cells [38] . Based on these observations, the association between prior radiation and survival on belagenpumatucel-L, which are consistent with data reported by the tecemotide (MUC1) vaccine [23] , generates an important hypothesis for the further study of tumour vaccines and should be considered in the design of future immunotherapy vaccine protocols.
While the overall trial did not meet its prespecified endpoint, additional analyses summarised in this paper indicate encouraging results in predefined subsets of patients. Most importantly, a clinically meaningful increase in overall survival was observed in the belagenpumatucel-L arm for patients who were randomised within 12 weeks of the completion of frontline chemotherapy. Furthermore, prolongation of survival was most notable in patients who received chemoRT prior to randomisation into this trial. Although the number of cases is small, a post hoc analysis showed that the effect or radiation was observed in the belagenpumatucel-L arm only, when radiation was given 6 months or less before randomisation. The toxicity profile of belagenpumatucel-L compares very favorably with that of the currently available maintenance therapies [7, 8] . Based on the suggested survival benefits described above, a confirmatory study of belagenpumatucel-L in these patient populations is warranted. Exploratory studies of combination of belagenpumatucel-L and PD-1 or PDL-1 are also warranted. 
